Replies to post #208547 on Biotech Values

[DewDiligence]

The bane of modest financial resources combined with modest efficacy.

You're quite right. OCRX will not go anywhere with the IV formulation of OCR-002 if they can't do better than HR=0.80 vs placebo. The company's task now is to get the dose up to the point where the efficacy is clinically meaningful. The AE profile suggests that this is an achievable goal.